OBJECTIVE To examine whether successful coronary reperfusion after thrombolytic treatment in patients with confirmed acute myocardial infarction can be diagnosed from the plasma marker fatty acid binding protein (FABP), for either acute clinical decision making or retrospective purposes.
DESIGN Retrospective substudy of the GUSTO trial.
SETTING 10 hospitals in four European countries.
PATIENTS 115 patients were treated with thrombolytic agents within six hours after the onset of acute myocardial infarction. Patency of the infarct related artery was determined by angiography within 120 minutes of the start of thrombolysis.
MAIN OUTCOME MEASURES First hour rate of increase in plasma FABP concentration after thrombolytic treatment, compared with increase in plasma myoglobin concentration and creatine kinase isoenzyme MB (CK-MB) activity. Infarct size was estimated from the cumulative release of the enzyme α hydroxybutyrate dehydrogenase in plasma during 72 hours, or from the sum of ST segment elevations on admission. Logistic regression analyses were performed to construct predictive models for patency.
RESULTS Complete reperfusion (TIMI 3) occurred in 50 patients, partial reperfusion (TIMI 2) in 36, and no reperfusion (TIMI 0+1) in 29. Receiver operating characteristic (ROC) curve analyses showed that the best performance of FABP was obtained when TIMI scores 2 and 3 were grouped and compared with TIMI score 0+1. The performance of FABP as a reperfusion marker was improved by combining it with α hydroxybutyrate dehydrogenase infarct size, but not with an early surrogate of infarct size (ST segment elevation on admission). In combination with infarct size FABP performed as well as myoglobin (areas under the ROC curve 0.868 and 0.857, respectively) and better than CK-MB (area = 0.796). At optimum cut off levels, positive predictive values were 97% for FABP, 95% for myoglobin, and 89% for CK-MB (without infarct size, 87%, 88%, and 87%, respectively), and negative predictive values were 55%, 52%, and 50%, respectively (without infarct size, 44%, 42%, and 34%).
CONCLUSIONS FABP and myoglobin perform equally well as reperfusion markers, and successful reperfusion can be assessed, with positive predictive values of 87% and 88%, or even 97% and 95% when infarct size is also taken into account. However, identification of non-reperfused patients remains a problem, as negative predictive values will generally remain below 70%.
- myocardial reperfusion
- cardiac marker proteins
Statistics from Altmetric.com
Thrombolytic treatment has become important in patients with acute myocardial infarction in order to reopen the infarct related artery and improve the survival of heart muscle. However, when this treatment has failed the patient may need other interventions such as angioplasty. In order to reach a decision on this, it is important to make a rapid, accurate, and non-invasive evaluation of the reperfusion status of the infarct related coronary artery after initial thrombolytic treatment. Relief of chest pain, normalisation of ST segment elevation on the ECG, and the occurrence of specific arrhythmias have been used as markers of reperfusion, but their sensitivity and specificity are limited.1 ,2 In addition, early washout and peaking of various cardiac proteins such as creatine kinase, creatine kinase MB isoenzyme (CK-MB), and myoglobin have been used to identify coronary reperfusion.3-6 Of these biochemical markers, myoglobin has been found most valuable because of its rapid release after opening of the vessel.3 ,6 ,7 More recently, a new plasma marker—fatty acid binding protein (FABP)—has become available, which resembles myoglobin in size (15 kDa), in its abundant presence in the cytoplasm of cardiomyocytes, and in its similarly rapid release into plasma after reperfusion.8 ,9 FABP has been found superior to myoglobin for the early detection of acute myocardial infarction.10 ,11
It was our aim in the present study to evaluate whether FABP can be used as a marker, either in acute clinical situations or retrospectively, to distinguish successful reperfusion from persistent occlusion after thrombolytic treatment in patients with confirmed acute myocardial infarction. We determined the increase in plasma concentrations of FABP in the first hour after thrombolytic treatment, and we also examined the increases occurring from 1–3 hours after thrombolysis as well as certain clinical variables (treatment delay, delay in performing angiography, infarct location). A comparison was made with the established markers myoglobin and CK-MB. The increase in cardiac proteins in the plasma after infarction is dependent on infarct size. We therefore assessed infarct size by an established method—the cumulative release of α hydroxybutyrate dehydrogenase during the first 72 hours after infarction.12 However, only a retrospective assessment of reperfusion status can be obtained in this way, though acute assessment is clinically more relevant. We therefore attempted to use an early surrogate for infarct size—initial ST segment elevation on the ECG.
Data were obtained from 124 patients with confirmed acute myocardial infarction, enrolled in the GUSTO (global utilisation of streptokinase and tissue plasminogen activator for occluded coronary arteries) enzyme substudy.13 Inclusion criteria for enrolment into the GUSTO study have been described in detail elsewhere.14 In summary, patients were eligible when they were admitted to hospital within six hours after the onset of symptoms, had chest pain lasting for at least 20 minutes, and showed ECG evidence of acute myocardial infarction (⩾ 0.1 mV of ST segment elevation in two or more limb leads, or ⩾ 0.2 mV in two or more contiguous precordial leads). Patients suspected of acute myocardial infarction received one of four intravenous thrombolytic regimens: streptokinase with subcutaneous heparin; streptokinase with intravenous heparin; accelerated tissue plasminogen activator (t-PA) with intravenous heparin; or the combination of t-PA and streptokinase, along with intravenous heparin.
Following thrombolytic treatment, coronary angiography was performed within 120 minutes (mean (SEM) 1.6 (0.2) hours, range 0.9–2.0 hours) to determine the reperfusion status of the infarct related artery. Flow in the infarct related artery was graded according to the thrombolysis in myocardial infarction (TIMI) trial classification.15Coronary arteries with TIMI grade 3 flow were regarded as successfully reperfused. Coronary arteries with TIMI grade 2 flow were regarded as partially open. TIMI grade 0 or 1 defined persistent occlusion.
Blood samples were collected immediately before and at 1, 3, 6, 12, 18, 24, 36, 48, 72, and 96 hours after the start of thrombolytic treatment, resulting in 11 samples/patient. Exact sampling time was recorded on the GUSTO enzyme case report form.13 Samples were collected in glass tubes containing dry heparin to prevent clotting. After routine centrifugation, plasma was kept at −20°C in the local hospital and within eight weeks was transported in polystyrene boxes with dry ice to the central laboratory at Maastricht, Netherlands, and stored at −80°C until assays were performed.
Heart type FABP was measured in duplicate in plasma samples by a non-competitive enzyme linked immunosorbent assay (ELISA) as described elsewhere,16 using an incubation time of 60 minutes. Samples were diluted with phosphate buffered saline (pH 7.4) containing 0.1% bovine serum albumin and 0.05% Tween-20. The detection limit of the assay was 0.2 μg/l. Quality control was performed with human plasma, spiked with recombinant human FABP. Intra-assay and interassay imprecision values were 4.2% and 9.0%, respectively. Myoglobin was determined in duplicate by a turbidimetric immunoassay (Unimate 3 Myo, art 0751839, Roche, Mijdrecht, Netherlands) on a Cobas Fara analyser (Roche Diagnostic Systems, Basel, Switzerland). Plasma samples were diluted with saline (0.9% NaCl). For quality control a commercial standard was used (Roche, art 075186). Intra-assay and interassay imprecision values were 3.5% and 4.0%, respectively. It has been reported in detail previously that FABP and myoglobin concentrations in plasma stored at −80°C, as in the present study, remain stable for several years.17 Plasma concentrations of FABP and myoglobin are expressed in μg/l.
Activities of CK-MB and α hydroxybutyrate dehydrogenase were measured spectrophotometrically in duplicate at 25°C, using a centrifugal analyser (Cobas Bio System, Roche) and commercially available test kits. The CK-MB test is based on immunoinhibition of the predominant M unit in creatine kinase (Boehringer Mannheim, Mannheim, Germany). The α hydroxybutyrate dehydrogenase test is based on the preferential catalytic activity of the myocardial isoforms LDH1 and LDH2 of lactate dehydrogenase in the conversion of α ketobutyrate, instead of pyruvate (Diagnostica Merck, Darmstadt, Germany). Quality control was performed using a commercially available control serum (Precipath, Boehringer Mannheim). Intra-assay and interassay imprecision values were 3.2% and 6.6% for CK-MB and 2.4% and 4.4% for α hydroxybutyrate dehydrogenase. Activities are expressed in micromoles of substrate converted per minute and litre of plasma (U/l).
CALCULATION OF THE INCREASE RATE OF PLASMA FABP, MYOGLOBIN, AND CK-MB
The first hour increases in plasma FABP, myoglobin, and CK-MB release were calculated by the difference in plasma concentrations or activity between the first two samples—that is, the samples just before (−0.11 (0.02) hours) and about one hour (1.14 (0.03)) after thrombolytic treatment, divided by the exact time between these two samples. The increase in plasma FABP, myoglobin, and CK-MB release was also determined from 1–3 hours (2.97 (0.02)) after thrombolytic treatment. The increase rates are expressed in μg/l/hour for FABP and myoglobin, and in U/l/hour for CK-MB.
DETERMINATION OF ENZYMATIC INFARCT SIZE
Infarct size was calculated from the cumulative release of α hydroxybutyrate dehydrogenase activity during 72 hours. Cumulative release of α hydroxybutyrate dehydrogenase per litre of plasma, from the onset of acute myocardial infarction (t = 0) up to time t, is indicated as Q(t) and was calculated from the following expression12:
The three terms are the quantity of released protein still present in plasma at time t, the extravasated quantity of protein at time t, and the quantity of protein eliminated from plasma up to time t, all three being expressed per litre of plasma.
C(t) is the plasma protein concentration or enzyme activity at time t, corrected by subtraction of normal steady state values, Cs. The latter were obtained from the lowest plasma values if they did not exceed the maximum value of 120 U/l for α hydroxybutyrate dehydrogenase. Otherwise, fixed mean values of 82 U/l were used. The variables TER and ERR represent the fractional rate constants for transcapillary escape and extravascular return of protein. Parameter values for α hydroxybutyrate dehydrogenase in man are TER = 0.014/h and ERR = 0.018/h.12 FCR is the fractional catabolic rate constant for the elimination of protein from plasma (0.015/h). Infarct size is expressed in gram equivalents of myocardium/litre of plasma (g eq/l). To this end, cumulative release of α hydroxybutyrate dehydrogenase/litre of plasma was divided by the mean myocardial content of α hydroxybutyrate dehydrogenase/g wet weight of tissue (123 U/g).
ST SEGMENT ELEVATION
The sum of ST segment elevations was obtained from admission ECG recordings. ST segment elevation and depression were measured at the J point of the ECG. The degree of elevation or depression was measured in millivolts. Total ST segment elevations were calculated as described elsewhere.18
Data analysis was performed with standard software (SPSS). Mean values (SEM) were calculated. Differences between the rates of increase in the TIMI groups were tested by the non-parametric Mann–Whitney rank test.
Predictive models for patency were constructed using logistic multiple regression. This method can be used when a binary classification, such as reperfusion versus non-reperfusion, is explained or predicted by a set of continuous variables19 (for example, first hour increase rate of a plasma marker concentration, infarct size, and so on). In the corresponding model the log odds of the probability of reperfusion (q) was expressed as a linear function of the explaining variables: log(q/(1−q)) = b0 + b1 × (first hour increase of FABP) + b2 × (infarct size).
Variables that contributed significantly to correct prediction of the classification were identified in a stepwise logistic regression procedure. Estimates of the variables b0, b1, . . . were obtained and for each case the estimated probability of reperfusion, q, was calculated. In our approach, q was used as an indicator of reperfusion analogous to the outcome in a diagnostic test. High values of q indicated reperfusion, low values indicated that reperfusion was not obtained. In order to distinguish high and low values, a cut off for q is required. In a receiver operating characteristic (ROC) curve, analysis of the relation between q and reperfusion, indicated by the TIMI score (true classification), was investigated for varying levels of cut off. The predictive value of a combination of predictors could thus be evaluated in a standard ROC analysis.
The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were determined as follows:
- Sensitivity—percentage of correctly identified patients with patent (TIMI 2 or 3) infarct related artery;
- Specificity—percentage of correctly identified patients with occluded (TIMI 0 or 1) infarct related artery;
- PPV—percentage of correctly identified patients with reperfusion;
- NPV—percentage of correctly identified patients with occlusion.
Plots were made of the sensitivity (true positive rate) against 1 − specificity (false positive rate) (ROC curve), and statistical comparison of the areas under the curve was performed according to a previously described method.20 Relations between variables were calculated by Pearson's correlation coefficients. Probability values of p < 0.05 were considered significant.
Patients who had cardioversion (n = 9) were excluded from the present study because of possible skeletal muscle damage. Baseline characteristics of the remaining 115 patients—93 men and 22 women—are shown in table 1. Except for the percentage of women, there were no significant differences in baseline characteristics, so for further analysis data from the four treatment groups were taken together. Fifty patients (43%) obtained a TIMI 3 score after angiography, 36 patients (31%) obtained a TIMI 2 score, while the other 29 patients (25%) had a score of TIMI 0 or 1. For the 115 patients studied, all variables that might be associated with reperfusion were complete.
PREDICTION OF REPERFUSION CONSIDERING TIMI 3 SCORE SEPARATELY OR COMBINED WITH TIMI SCORE 2
The concentrations of FABP, myoglobin, and CK-MB in plasma samples obtained immediately before thrombolytic treatment did not differ significantly among the TIMI score groups (data not shown). One hour after thrombolytic treatment, plasma FABP, myoglobin, and CK-MB concentrations had increased significantly more in the TIMI 2 and 3 patients (p < 0.005 for FABP and myoglobin, p < 0.05 for CK-MB) than in the TIMI 0 or TIMI 1 patients, but for each marker the increases were not significantly different between the TIMI 2 and TIMI 3 patients (fig 1 and data not shown).
Figure 2A shows the ROC curves of the first hour increase in FABP release when patency was defined as TIMI 3 alone or as TIMI 2+3, and occlusion was defined as either TIMI 0+1 or TIMI 0+1+2. The area under the ROC curve was highest when TIMI 2+3 values were compared with TIMI 0+1 (area = 0.760), slightly smaller when TIMI 3 was compared with TIMI 0+1 (area = 0.706, p < 0.05), and smallest when TIMI 3 was compared with TIMI 0+1+2 (area = 0.530, p < 0.001). For myoglobin similar results were obtained (data not shown). Further analysis was therefore performed on the TIMI 2+3 patients versus the TIMI 0+1 patients. The probability of reperfusion (q) on the basis of the first hour increase rate of FABP could be estimated by log (q/1−q) = 0.1367 + 0.0097 × (first hour increase rate of FABP).
PREDICTION OF REPERFUSION BY FABP, PATIENT CHARACTERISTICS, CLINICAL VARIABLES, AND INFARCT SIZE
We attempted to improve discrimination between reperfused (TIMI 2+3) and non-reperfused patients (TIMI 0+1) by combining the first hour increase in FABP release with the 1–3 hour increase in FABP release, some characteristics of the patients (age, sex), clinical variables (treatment delay, catheterisation delay, infarct location), and infarct size (as measured either by the cumulative release of α hydroxybutyrate dehydrogenase into plasma in the first 72 hours (QHBDH72) or by ST segment elevation). Forward stepwise logistic regression analysis indicated that prediction of reperfusion was not improved by adding the 1–3 hour increase in FABP release, the patient characteristics, or the clinical variables to the model (p > 0.05), nor did the addition of infarct size, as measured by ST segment elevation, improve discrimination between reperfused and non-reperfused patients (fig 2B, area under the ROC curve 0.772). In contrast, the addition of infarct size as measured by QHBDH72 did improve discrimination between reperfused and non-reperfused patients (fig 2B, area under the ROC curve 0.868, p < 0.001).
The probability of reperfusion (q) on basis of the first hour increase in FABP release and enzymatic infarct size could be estimated by: log (q/1−q) = 1.6542 + 0.0132 × (first hour increase rate of FABP) − 0.4054 × (enzymatic infarct size). The negative value of b2 corrects for the extra rapid first hour increase rates in case of larger infarctions.
COMPARISON OF FABP, MYOGLOBIN, AND CK-MB AS REPERFUSION MARKERS
As with FABP, the reperfusion predicting model was improved when the first hour increase in myoglobin release was combined with enzymatic infarct size (the values of b0, b1, and b2 were 1.6839, 0.0034, and −0.3905, respectively, while ROC curve areas for myoglobin alone and for myoglobin in combination with enzymatic infarct size were 0.718 and 0.857, p = 0.004, fig 3A and 3B). The area under the ROC curve of the first hour increase rate of CK-MB release was also augmented by adding enzymatic infarct size to the model (0.681 and 0.769, respectively, p = 0.04; values of b0, b1, and b2 were 1.9102, 0.0736, and −0.2402, respectively.). The areas under the ROC curve for the first hour increase in FABP and myoglobin release combined with enzymatic infarct size were both larger than for CK-MB (p = 0.046 and p = 0.028, respectively) (fig 3A and 3B).
Using the ROC curves, optimum points (giving the maximum sum of sensitivity and specificity) of the first hour increase in release of FABP, myoglobin, and CK-MB were determined. In addition to sensitivity and specificity, the positive and negative predictive values were calculated at these points (table 2). Various probabilities of reperfusion predicted by FABP are also shown in combination with these variables (table 3).
In this multicentre study, FABP was used as a marker to distinguish successful reperfusion from persistent occlusion after thrombolytic treatment in a large group of patients with confirmed acute myocardial infarction. The definition of reperfusion was either TIMI 2+3 score or TIMI 3 score alone. Our findings indicate that the best discrimination between reperfusion and occlusion by plasma FABP or myoglobin was obtained when TIMI 2+3 were classified as reperfusion and TIMI 0+1 as occlusion. FABP was found to perform as well as plasma myoglobin, while both variables performed better than CK-MB. For acute clinical decision making, the accuracy of the first hour increase in FABP release appeared too low. However, in retrospective studies it may be useful to include both the first hour increase in FABP (or myoglobin) release and the enzymatic infarct size in the predictive model.
FIRST HOUR INCREASE RATE OF FABP RELEASE AFTER THROMBOLYSIS AS A REPERFUSION MARKER
FABP is a small cytoplasmic protein (15 kDa), like myoglobin (17.8 kDa), which is rapidly released from injured myocardium and enters the bloodstream when the occluded artery is reopened by thrombolytic agents.21 ,22 Peak values are reached on average within six hours after the onset of acute myocardial infarction and return to normal within 24 hours.8 ,21 ,22 Earlier studies used the time to the peak plasma concentration to assess the value of serum markers for discriminating between reperfused and non-reperfused patients. For myoglobin, Zabel and colleagues showed that measurement of the early initial slope gives a more accurate assessment of reperfusion than the time to peak concentration, and it is also more rapidly available.6 The first hour increase in release can be assessed either as an absolute value (value at time t − value at time 0/dt) or relatively (value at time t/value at time 0). In an ROC curve analysis for myoglobin, Tanasijevic and colleagues found no differences in discrimination when comparing absolute or relative early slope values.23 In the present study the absolute first hour increase in FABP release was assessed, and the individual data showed great variation and considerable overlap in the first hour release values among the various TIMI scores.
DEFINITION OF REPERFUSION
In many studies, TIMI 2 and 3 patients have been grouped and classified as being reperfused.6 ,7 ,21 ,23-27 However, a study by Anderson and colleagues showed that TIMI grade 3 blood flow resulted in improved patient outcome compared with grade 2 flow.28 For this reason, the TIMI 3 score alone may be defined as successful reperfusion, while the TIMI 2 score represents an intermediate point between TIMI 3 and TIMI 0+1. In the present study we considered both TIMI 3 only and TIMI 2+3 combined as reperfusion. The results for TIMI 3 v TIMI 0+1 orv 0+1+2 were less satisfactory, while the best performance with FABP was obtained when both TIMI 2 and 3 groups were considered as being reperfused. The results were similar for myoglobin and CK-MB (data not shown). Hence FABP may be useful as a reperfusion marker in discriminating between TIMI 2+3v TIMI 0+1, but not in differentiating between TIMI 2 or TIMI 3. Similarly, Christenson and colleagues reported a better performance for myoglobin when TIMI 2+3 were compared with TIMI 0+1, rather than when comparing TIMI 3 with TIMI 0+1+2.27 Moreover, Apple recently concluded that TIMI 3 flow patients cannot be differentiated from TIMI 2 patients by using biochemical markers.29
INCLUDING INFARCT SIZE IN THE MODEL
When the amount of necrosis is small, the first hour increase in release of cell components may be low and values found in the reperfused group may overlap with those seen in patients without reperfusion but with larger infarcts. This overlap can be reduced when rates of release are combined with enzymatic infarct size in the model. However, a drawback of using the cumulative release of α hydroxybutyrate dehydrogenase over 72 hours as a measure of infarct size is the long time necessary for sample collection; hence this method is only useful in retrospective studies. Because of this, we also evaluated the use of the sum of the initial ST elevations as a surrogate for infarct size. A very weak correlation was found between the sum of ST elevations and the cumulative release of α hydroxybutyrate dehydrogenase over 72 hours (r = 0.36, fig 4). Similarly, Willems and colleagues also showed a poor correlation between the sum of the initial ST elevations and enzymatic infarct size (r = 0.32).30 On the other hand, Yusuf and associates found a much higher correlation (r = 0.73), but they used a more refined technique (precordial mapping) to evaluate ST deviations.31 Using the sum of ST segment elevation in our study, no improvement of discrimination between reperfused and non-reperfused patients could be obtained (fig 2B).
COMPARISON OF FABP, MYOGLOBIN, AND CK-MB AS REPERFUSION MARKERS
Various biochemical markers of myocardial necrosis have been used to detect reperfusion non-invasively after thrombolysis. These include measurement of myoglobin and CK-MB.5 ,6 ,25-27 In the present study, we compared FABP with myoglobin and CK-MB as reperfusion marker by ROC curve analysis. Similar results were found for FABP and myoglobin, while CK-MB was slightly worse as a reperfusion marker. These findings are in line with earlier studies in indicating more accurate detection of reperfusion by myoglobin than by CK-MB,6 ,24 ,25 while in a very recent study by Ishii and colleagues on 45 patients, comparable results were obtained for FABP and myoglobin.21 FABP is relatively more cardiospecific than myoglobin as the (heart type) FABP content of skeletal muscle is considerably less than in cardiac muscle, while the muscular content of myoglobin is approximately twice that of the heart (when expressed per g wet weight of muscle).22 In case of muscle injury—for example, electrical defibrillation, intramuscular injection, or trauma—the serum concentration of myoglobin will rise rapidly and hence false positive results could be obtained. However, in the present work, as well as in that of Ishii and colleagues, patients with these conditions were excluded.21
The sensitivity and specificity of FABP, myoglobin, and CK-MB, calculated at the optimum points of the ROC curve, were not as high in the present study as in others (table 4). This may reflect the fact that in the present study blood sampling was not accompanied by repeated angiography and so the exact timing of the reopening of the vessel was not known. Increased rates of cell component release were determined during the first hour after thrombolytic treatment, while the angiogram was taken later (between 0.9 and 2.0 hours after treatment). A discrepancy between protein indices and angiographic assessment of reperfusion may have occurred in patients with late reperfusion, early spontaneous reperfusion, or reocclusion of the infarct related artery after initial successful thrombolysis. In an attempt to account for late reperfusion, we added the increase rate of FABP (per hour) at 1–3 hours after thrombolytic treatment to our model, but no additional discrimination was obtained. However, the possibility of early spontaneous reperfusion or reocclusion after initial successful thrombolysis could not be excluded, because a pretreatment coronary angiogram was missing and because of insufficient blood sampling. Notwithstanding these considerations, our data still allow an adequate comparison of the performance of the three plasma markers studied.
In the absence of angiography, it is important that the FABP test can identify patients with persistent occlusion, because such patients can be treated by other interventions such as rescue percutaneous transluminal coronary angioplasty. Thus both the negative predictive value and the specificity were considered. At the optimal point in the curve, the negative predictive value—indicating the percentage of correctly identified patients with decreased rates of release—was low (table 2). The negative predictive value is related to the prevalence of non-reperfused patients, which was relatively low (25%) in the present study. The optimum specificity of the first hour increase in release of FABP was 69%. In practice, this would mean that on the basis of the first hour increase in FABP release, 31% of the patients with TIMI 0 or 1 score would not be treated further after failing thrombolytic treatment—a rather high percentage. When the specificity increases—that is, fewer patients with closed infarct related arteries are missed—the sensitivity simultaneously decreases (more patients with adequate perfusion after thrombolytic treatment will be treated unnecessarily). It depends on the clinical management which factor (sensitivity or specificity) is regarded as the most important. By using two probability values and disregarding the patients who fell in between, a population of patients with acute myocardial infarction treated with thrombolytic agents and without coronary angiography could be divided into a reperfused group and a non-reperfused group. Table 3 shows that in this way a group of patients with a > 97% chance of successful reperfusion and a group with a > 75% chance of non-reperfusion could be obtained by retrospective study. The latter figure of 75% is relatively low because of the low first hour increase in rate of FABP in reperfused patients with small infarcts. This figure would thus have been higher if our analyses had been restricted to patients with a certain minimum infarct size (for example, 1 g eq/l).
The performance of FABP as a reperfusion marker is greatly improved by including enzymatic infarct size in the model. For example, a patient with an average first hour increase of plasma FABP of 200 μg/l/h and a large infarct (> 10 g eq/l)—according to the formula presented in the legend to table 3—would only have a < 63% chance (that is, q = 0.63) of successful reperfusion, whereas if this patient had a small infarct (< 1 g eq/l) the chance of successful reperfusion would be > 99% (that is, q = 0.99).
As a non-invasive reperfusion marker, FABP performs as well as myoglobin. Our data indicate that for acute clinical decision making there is inadequate discrimination between reperfusion and non-reperfusion using this method, but in retrospective studies discrimination can be improved by considering both the increase rate of plasma FABP and the enzymatically determined infarct size.
We gratefully acknowledge the expert technical assistance of Y F de Jong, M M A L Pelsers, M A J G Fischer, M L Mullers-Boumans, and B Kop-Klaassen. The study was supported by the Netherlands Heart Foundation grant 95.189.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.